Boston Scientific

(BSX) - Get Report

shares were revived today when the company announced regulatory approval for expanded use of company's stents.

Shares rose 63 cents, or 2.2%, to $29.92, off a near 52-week low, after the Food and Drug Administration said patients with the drug-eluting Taxus Express2 and the bare metal Express2 stents implanted could now undergo magnetic resonance imaging immediately after surgery. It's the first such approval, and it represents something of an advantage over rival

Johnson & Johnson

(JNJ) - Get Report

.

Patients typically have to wait two months after having the metal tubes implanted before getting an MRI scan, because magnetic fields may cause a stent to migrate or heat in the body. An MRI uses a magnetic field to view tissues and organs in the body, and after heart surgery it can be used to look at heart valves and coronary blood vessels to detect damage.

Taxus stents were safe within the high magnetic field strengths, with little effect on temperature and the controlled release of the drug coating, according to company's tests. Stents are used to prop open blood vessels in patients with cardiovascular diseases, and the Taxus Express2 is coated by the drug paclitaxel, which allows healing while reducing regrowth of excess tissue causing further blockage.

Shares of Boston Scientific's partner

Angiotech Pharmaceuticals

(ANPI)

were up 44 cents, or 2.88% to 15.72.